Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Global Combined Hormonal Contraceptives (CHC) Market: Trends and Opportunities (2014-19)The report titled “Global Combined Hormonal Contraceptive (CHC) Market: Trends and Opportunities (2014-2019)” provides an in-depth analysis of the global CHC market with detailed analysis of market sizing and growth, market share.
By: Daedal Research Country Coverage United states United Kingdom India China Japan Company Coverage Agile Therapeutics Inc. Actavis Plc. Bayer Healthcare Teva Pharmaceuticals Executive Summary Combined Hormonal Contraceptives (CHC) is widely being used as an effective and reversible birth control method. Mainly used for preventing pregnancies but sometimes also used for treating acne vulgaris, endometriosis, polycystic ovarian syndrome and irregular menstrual flow, CHC works by preventing ovulation i.e. release of egg from ovaries. The hormones are provided in the combined pill, patch or ring. Most popular Combined Hormonal Contraceptives products are Nuvaring and Ortho Evra. CHC products are broadly used throughout the world by women in the age-group of 15 to 49 years. With increasing health consciousness and awareness, adoption of CHC products or birth control methods is increasing in lesser privileged economic segments too. The growth of CHC market is driven by urbanization and increasing user awareness, rise in menstruating population globally and initiatives taken by governments to encourage the use of contraception. Major trends prevailing in the market are the increasing number of mergers and acquisitions in this business space and demand for reversible method of contraception with fewer side effects. Table of Contents: 1. Executive Summary 2. Combined Hormonal Contraceptives Market: An Overview 2.1 Definition 2.2 History 2.3 Classification 2.3.1 Combined Oral Contraceptive Pills 2.3.2 Combined Vaginal Rings 2.3.3 Combined Transdermal Patches 2.3.4 Combined Injectable Birth Control 2.3.5 Combined Emergency Contraceptive Pills 2.4 Mechanism of Action 2.5 Components of CHCs 2.6 Advantages of Combined Hormonal Contraceptives 2.7 Disadvantages of Combined Hormonal Contraceptives 2.8 Contraindications 2.9 Serious Risks 3. Combined Hormonal Contraceptives (CHC) Market Analysis 3.1 Global CHC Market Sizing and Growth 3.2 Global CHC Market Breakup: Branded vs. Generic 3.3 CHC Generic Market 3.4 Global CHC Branded Market 4. Combined Hormonal Contraceptives (CHC): Market Share Analysis 4.2.1 Global CHC Market Share by Class 4.2.2 Global CHC Market Share by Key Players 4.2.3 Global CHC Market Share by Key Products 5. Combined Hormonal Contraceptives (CHC): Country Analysis 5.1 The U.S. Combined Hormonal Contraceptives Market 5.2 The UK Combined Hormonal Contraceptives Market 5.3 Japan Combined Hormonal Contraceptives Market 5.4 India Combined Hormonal Contraceptives Market 5.5 China Combined Hormonal Contraceptives Market 6. Market Dynamics: Combined Hormonal Contraceptives (CHC) Market 6.1 Growth Drivers 6.1.1 Rise in Healthcare Expenditure 6.1.2 Growth in the U.S. Contraceptive Market 6.1.3 Government Initiatives 6.1.4 The Prescriber Base is Easily Targeted 6.2 Challenges 6.2.1 Strict Regulatory Compliance 6.2.2 Serious Adverse Events 6.3 Market Trends 6.3.1 Significant M&A activity in Women’s Health Market 6.3.2 Use of Newer Progestins 7. Competitive Landscape: Combined Hormonal Contraceptives (CHC) Market 8. Company Profiles: Combined Hormonal Contraceptives (CHC) Market 8.1 Agile therapeutics, Inc. 8.1.1 Business Overview 8.1.2 Financial Overview 8.1.3 Business Strategy 8.2 Actavis Plc. 8.2.1 Business Overview 8.2.2 Financial Overview 8.2.3 Business Strategy 8.3 Bayer Healthcare 8.3.1 Business Overview 8.3.2 Financial Overview 8.3.3 Business Strategy 8.4 Teva Pharmaceutical Industries Limited 8.4.1 Business Overview 8.4.2 Financial Overview 8.4.3 Business Strategies List of Figure: Figure 1: Types of Combined Hormonal Contraceptives Figure 2: Fixed Dose Microgynon® 30 ED Figure 3: Combined Vaginal Rings Figure 4: Twirla Patch Components Figure 5: Mechanism of Action Figure 6: Annual Sales of Global CHC Market; 2008-2013 (US$ Million) Figure 7: Global CHC Market Size by Annual Sales Forecasted; 2014-2019E (US$ Million) Figure 8: Global CHC Market Breakup: Branded vs. Generic Figure 9: Annual Sales of Global Generic CHC Market; 2008-2013 (US$ Million) Figure 10: Annual Sales of Global Branded CHC Market; 2008-2013 (US$ Million) Figure 11: Global CHC Market Share by Class; 2013 Figure 12: Global CHC Market Share by Key Players; 2013 Figure 13: Global CHC Market Share by Key Products; 2013 Figure 14: Women Population Aged 15-49 years in Seven Major Markets; 2013 (Thousands) Figure 15: Women Population Aged 15-49 years in Seven Major Market taking Hormonal contraception by class; 2010-2013 (Thousands) Figure 16: Women Population Aged 15-49 years in Seven Major Market taking Hormonal Contraception Forecasted; 2014-2019 (Thousands) Table 1: Key Oral Contraceptives (OC) TRx (million) Figure 17: U.S. Oral Contraceptive TRx Breakdown; 2013 (US$ 4 billion) Figure 18: U.S. Oral Contraceptive Sales Breakdown; 2013 (US$ 4 billion) Figure 19: Indian versus MNC generic’s TRx share; 2013 Figure 20: Healthcare Expenditure Worldwide; 2007-2013 (US$ Million) Figure 21: Population - Women aged 15-44 years in the US: 2008-2020 (Thousands) Figure 22: US CHC Market -Quarterly Prescription Growth (%) Table 2: Leading Players of Hormonal Contraceptives Market Table 3: Hormonal Contraception Market: Key Players and their Marketed Products and Pipeline Products Figure 23: Global Sales of Key Products: FY 2013 (US$ Million) Figure 24: Twirla Patch Components Figure 25: Skinfusion Technology Table 4: Agile Therapeutics Product Pipeline Figure 26: Agile Net Revenue Forecasted: 2016-2021 (US$ Million) Figure27: Actavis Plc. Net Revenue (consolidated): Figure 28: Actavis specialty brand; Net Revenue and Product Sales (consolidated): For further details, kindly visit : http://www.daedal- Rajeev Kumar (Business Development Manager) Address: 36 SFS Flats Paschim Vihar New Delhi-110063 Mobile: +91-8743975789 Tel: +91-120-4553017 Mail ID - info@daedal- Daedal Research is a research and consulting firm specialized in providing research reports and customized business research and analysis. For more Information: http://www.daedal- End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|